Capecitabine
Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine antimetabolite widely used in oncology.
Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine antimetabolite widely used in oncology. Following absorption, capecitabine undergoes a sequential three-step enzymatic conversion — first in the liver and then preferentially within tumor tissue — culminating in the release of active 5-FU. This tumor-preferential activation is mediated by thymidine phosphorylase, which is overexpressed in many malignancies, thereby concentrating cytotoxic activity preferentially at the tumor site, although normal tissues are also affected. Once converted to 5-FU, the drug inhibits thymidylate synthase, disrupting DNA synthesis and inducing cell death in rapidly proliferating cancer cells. Capecitabine is approved for the treatment of multiple solid tumors, including colorectal cancer, gastric cancer, and breast cancer, and is frequently combined with platinum-based agents, targeted therapies, and immune checkpoint inhibitors to enhance efficacy.
As a cornerstone of combination regimens, capecitabine offers the practical advantage of oral administration over intravenous 5-FU infusion, improving patient convenience and quality of life. Its combination with oxaliplatin — commonly designated CAPOX or XELOX — is a standard-of-care backbone in gastric, gastro-oesophageal junction (GEJ), and colorectal cancers. The drug is also employed in maintenance and frailty-adapted dosing strategies, reflecting its versatility across diverse patient populations and disease stages.
- Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study). PMID 43035449
Where the papers sit
17 papers from the last 6 months study capecitabine directly
Study type 4 clinical trials · 6 observational · 5 human data · 2 preclinical
Themes one subject · 1 new direction
Those 17 are all about one subject.
-
Oral Fluoropyrimidine Therapy
Oral fluoropyrimidines are being extended across perioperative, adjuvant, and metastatic treatment, often in combinations with trastuzumab, bevacizumab, gemcitabine, or nab-paclitaxel. S-1 and capecitabine studies repeatedly assess tumour control alongside dose intensity, nutritional status, and patient-managed toxicity. DPYD variants and adverse-effect monitoring are emerging as practical determinants of safe dosing, while machine-learning tools aim to predict acute-care needs. Chemoresistance mechanisms including CAF remodeling and RAD51AP1 stabilization remain open targets.
Capecitabine is repositioned as a co-encapsulated nanocarrier payload rather than solely an oral systemic chemotherapy
The dual-drug-loaded lipid formulation for colon cancer therapeutics used capecitabine and celecoxib as co-encapsulated agents in optimized liposomes, evaluating their physicochemical properties, release, stability, and in-vitro suitability for colon cancer treatment 42467220Jul. This departs from the set’s clinical use of capecitabine as an orally administered component of chemotherapy or maintenance therapy by assigning it a new drug-delivery role: a payload in a combined lipid-based nanocarrier intended to alter how capecitabine and a second drug are delivered.
Papers
The 17 papers from the last 6 months that study capecitabine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Oral Fluoropyrimidine Therapy (17)
- Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study). Journal of hematology & oncology · 15 Nov 2026 PMID 43035449
- Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study. Cancer · 1 Nov 2026 PMID 42967221
- Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer research · 31 Aug 2026 PMID 42674690
- Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665401
- Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665382
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States. Breast cancer research and treatment · 12 Aug 2026 PMID 42584742
- A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer. Cancer chemotherapy and pharmacology · 3 Aug 2026 PMID 42545499
- Long-term Outcomes of OGSG1108: A Supplemental Study of Oral Nutritional Supplementation During Adjuvant S-1 Chemotherapy. Anticancer research · 29 Jul 2026 PMID 42527082
- Dual-drug-loaded lipid-based formulation for colon cancer therapeutics: in vitro optimization and characterization. Drug development and industrial pharmacy · 17 Jul 2026 PMID 42467220
- Machine Learning-based Prediction of Unplanned Acute Care in Outpatients Receiving S-1 Chemotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379750
- Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. Breast cancer research and treatment · 26 Jun 2026 PMID 42360572
- The Impact of Side Effects on Oral Anticancer Agent Self-Management: Patient Perception of Risks Matters. Oncology nursing forum · 24 Jun 2026 PMID 42341331
- Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Signal transduction and targeted therapy · 21 Jun 2026 PMID 42324245
- PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. Cancer research · 18 Jun 2026 PMID 42314057
- Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. Signal transduction and targeted therapy · 21 May 2026 PMID 42168151
By study type
Clinical trials (4)
- Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study). Journal of hematology & oncology · 15 Nov 2026 PMID 43035449
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Signal transduction and targeted therapy · 21 Jun 2026 PMID 42324245
- Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. Signal transduction and targeted therapy · 21 May 2026 PMID 42168151
Observational studies and case reports (6)
- Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Anticancer research · 31 Aug 2026 PMID 42674690
- Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665401
- Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665382
- Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States. Breast cancer research and treatment · 12 Aug 2026 PMID 42584742
- A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer. Cancer chemotherapy and pharmacology · 3 Aug 2026 PMID 42545499
- Machine Learning-based Prediction of Unplanned Acute Care in Outpatients Receiving S-1 Chemotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379750
Human data, design not indexed (5)
- Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study. Cancer · 1 Nov 2026 PMID 42967221
- Long-term Outcomes of OGSG1108: A Supplemental Study of Oral Nutritional Supplementation During Adjuvant S-1 Chemotherapy. Anticancer research · 29 Jul 2026 PMID 42527082
- Dual-drug-loaded lipid-based formulation for colon cancer therapeutics: in vitro optimization and characterization. Drug development and industrial pharmacy · 17 Jul 2026 PMID 42467220
- Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. Breast cancer research and treatment · 26 Jun 2026 PMID 42360572
- The Impact of Side Effects on Oral Anticancer Agent Self-Management: Patient Perception of Risks Matters. Oncology nursing forum · 24 Jun 2026 PMID 42341331
Preclinical: animal, cell and lab studies (2)
- Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS. Human cell · 24 Aug 2026 PMID 42635882
- PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. Cancer research · 18 Jun 2026 PMID 42314057
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-02 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.